These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 34731461)

  • 1. Inhaled Phosphodiesterase Inhibitors for the Treatment of Chronic Obstructive Pulmonary Disease.
    Singh D; Lea S; Mathioudakis AG
    Drugs; 2021 Nov; 81(16):1821-1830. PubMed ID: 34731461
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phosphodiesterase 4 inhibitors for the treatment of chronic obstructive pulmonary disease: a review of current and developing drugs.
    Mulhall AM; Droege CA; Ernst NE; Panos RJ; Zafar MA
    Expert Opin Investig Drugs; 2015; 24(12):1597-611. PubMed ID: 26419847
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Update on roflumilast, a phosphodiesterase 4 inhibitor for the treatment of chronic obstructive pulmonary disease.
    Rabe KF
    Br J Pharmacol; 2011 May; 163(1):53-67. PubMed ID: 21232047
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease.
    Chong J; Leung B; Poole P
    Cochrane Database Syst Rev; 2013 Nov; (11):CD002309. PubMed ID: 24190161
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The modulatory effects of the PDE4 inhibitors CHF6001 and roflumilast in alveolar macrophages and lung tissue from COPD patients.
    Lea S; Metryka A; Li J; Higham A; Bridgewood C; Villetti G; Civelli M; Facchinetti F; Singh D
    Cytokine; 2019 Nov; 123():154739. PubMed ID: 31319374
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of roflumilast in COPD patients receiving inhaled corticosteroid/long-acting β2-agonist fixed-dose combination: RE(2)SPOND rationale and study design.
    Rennard SI; Martinez FJ; Rabe KF; Sethi S; Pizzichini E; McIvor A; Siddiqui S; Anzueto A; Zhu H
    Int J Chron Obstruct Pulmon Dis; 2016; 11():1921-8. PubMed ID: 27574416
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The preclinical pharmacology of roflumilast--a selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease.
    Hatzelmann A; Morcillo EJ; Lungarella G; Adnot S; Sanjar S; Beume R; Schudt C; Tenor H
    Pulm Pharmacol Ther; 2010 Aug; 23(4):235-56. PubMed ID: 20381629
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Considerations for Roflumilast: A New Treatment for COPD.
    Kelly Freeman ML
    Consult Pharm; 2012 Mar; 27(3):189-93. PubMed ID: 22421519
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel inhaled phosphodiesterase 4 inhibitor (CHF6001) reduces the allergen challenge response in asthmatic patients.
    Singh D; Leaker B; Boyce M; Nandeuil MA; Collarini S; Mariotti F; Santoro D; Barnes PJ
    Pulm Pharmacol Ther; 2016 Oct; 40():1-6. PubMed ID: 27373438
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ensifentrine (RPL554): an inhaled 'bifunctional' dual PDE3/4 inhibitor for the treatment of asthma and chronic obstructive pulmonary disease.
    Cazzola M; Page C; Calzetta L; Matera MG
    Pharm Pat Anal; 2018 Nov; 7(6):249-257. PubMed ID: 30657422
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A dose-ranging study of the inhaled dual phosphodiesterase 3 and 4 inhibitor ensifentrine in COPD.
    Singh D; Martinez FJ; Watz H; Bengtsson T; Maurer BT
    Respir Res; 2020 Feb; 21(1):47. PubMed ID: 32041601
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease.
    Chong J; Poole P; Leung B; Black PN
    Cochrane Database Syst Rev; 2011 May; (5):CD002309. PubMed ID: 21563134
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Roflumilast for severe COPD?
    Drug Ther Bull; 2011 Apr; 49(4):45-8; quiz iii-iv. PubMed ID: 21467576
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acute treatment with the PDE4 inhibitor roflumilast improves verbal word memory in healthy old individuals: a double-blind placebo-controlled study.
    Blokland A; Van Duinen MA; Sambeth A; Heckman PRA; Tsai M; Lahu G; Uz T; Prickaerts J
    Neurobiol Aging; 2019 May; 77():37-43. PubMed ID: 30776650
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Roflumilast in the management of chronic obstructive pulmonary disease.
    Lipari M; Benipal H; Kale-Pradhan P
    Am J Health Syst Pharm; 2013 Dec; 70(23):2087-95. PubMed ID: 24249758
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Roflumilast (Daliresp) for COPD.
    Med Lett Drugs Ther; 2011 Jul; 53(1369):59-60. PubMed ID: 21778965
    [No Abstract]   [Full Text] [Related]  

  • 17. What role will ensifentrine play in the future treatment of chronic obstructive pulmonary disease patients? Implications from recent clinical trials.
    Cazzola M; Page C; Calzetta L; Singh D; Rogliani P; Matera MG
    Immunotherapy; 2023 Dec; 15(18):1511-1519. PubMed ID: 37779474
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of CHF6001, a novel inhaled PDE4 inhibitor in COPD: the PIONEER study.
    Singh D; Emirova A; Francisco C; Santoro D; Govoni M; Nandeuil MA
    Respir Res; 2020 Sep; 21(1):246. PubMed ID: 32962709
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ensifentrine: First Approval.
    Keam SJ
    Drugs; 2024 Sep; 84(9):1157-1163. PubMed ID: 39196510
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Roflumilast for COPD.
    Izquierdo JL; Aparicio J
    Drugs Today (Barc); 2010 Nov; 46(11):823-31. PubMed ID: 21225021
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.